Polytope monoclonal antibody candidates are being developed by ImmunoPrecise Antibodies (IPA) in collaboration with EVQLV for the treatment of COVID-19 infections. EVQLV, an artificial intelligence company will utilise B cell selectTM, Single Step Cloning Hybridoma, and custom DeepDisplayTM platforms developed at IPA. B cell selectTM platform enables the interrogation of B-cells to generate native monoclonal antibodies from any immunised animal, independent of species. DeepDisplayTM platform is a combination of phage display platform which contains immune libraries from different animal species including transgenic animals and Ligand's OmniAb therapeutic antibody platform which develop fully human antibody with reduced immunogenicity. EVQLV will perform in-silico antibody design to discover novel antibody sequence to leverage lead candidate from IPA's discovery platform. Early research is underway in US.
In June 2020, ImmunoPrecise Antibodies (IPA) and LiteVax entered an R & D agreement to conduct preclinical studies for analysis of the immunogenicity, safety and potency of ImmunoPrecise Antibodies' SARS-CoV-2 vaccine candidates, upon being formulated with LiteVax’s Adjuvant (LVA). The studies have been completely funded by TRANSVAC2, a network of leading European groups working in the field of vaccine development. The aim of this collaboration is to conduct preclinical analyses with PA’s protein-based vaccine candidates that are formulated with LVA (adjuvant) and assess for the potent, neutralizing antibody responses against SARS-CoV-2 infection in a swine model. Protein-based vaccine candidates will be supplied by ImmunoPrecise and LVA will be supplied by LiteVax. According to the agreement, both companies will retain full rights to their respective proprietary assets and know-how used for the study. If the preclinical studies are a success, IPA and LiteVax may negotiate the terms for a preclinical study in a second animal model, and the details of the potential commercialization of any resulting vaccine. Financial details of the agreement have not been disclosed. 
In March 2020, ImmunoPrecise Antibody and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against COVID-19. Under the terms of the agreement, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV will utilise its in-silico antibody design to generate novel antibody sequence by using IPA's B cell selectTM and custom deep displayTM technology platform to discover lead candidate against SARS-CoV-2 coronavirus infection.
Key Development Milestones
In November 2020, ImmunoPrecise Antibodies announced nomination of the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing that will evaluate its safety, tolerability and efficacy in the well defined SARS-CoV-2, Syrian hamster model  .
ImmunoPrecise Antibodies, in July 2020, announced the identification of additional human lead antibody candidates against SARS-CoV-2, that demonstrate potent in vitro neutralizing activity, and have been discovered using Ligand's OmniRat® therapeutic human antibody platform  .In June 2020, ImmunoPrecise announced discovery of functional antibodies from the top 300 lead antibodies analysed from human and llama  .
In June 2020, ImmunoPrecise Antibodies announced that they intend to conduct preclinical trial with polytope monoclonal antibody candidates in collaboration with LiteVax in August 2020. The preclinical study will determine immunogenicity, safety and potency of the candidates with an adjuvant provided by LiteVax. The study will be funded by TRANSVAC2  .
In March 2020, EVQLV submitted the first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2  .